GSK Phase II Study Signals Efimosfermin Potential in MASH Fibrosis
A GSK Phase II study points to efimosfermin's potential to improve liver fibrosis in patients with MASH.
Related stories
Banco Mercantil Reports R$ 279.4 Million Third-Quarter Profit
Banco Mercantil reported profit of R$ 279.4 million in the third quarter, marking its 16th consecutive record.
M impact | EQUITY | Nov 05, 2026, 03:42 PM UTC
ABC Brasil Reports R$273.7 Million Third-Quarter Profit
Brazilian bank ABC Brasil reported third-quarter profit of R$273.7 million.
M impact | EQUITY | Nov 05, 2026, 03:42 PM UTC
FGC Reports System Intrusion and Personal Data Leak
Brazil’s Fundo Garantidor de Créditos (FGC) reports an intrusion into its system and a leak of personal data.
M impact | EQUITY | Nov 05, 2026, 03:42 PM UTC
Evergy raises 2026 profit forecast after Q3 beat; shares climb 2.6%
Evergy lifted its 2026 profit forecast after beating expectations in the third quarter. Shares rose 2.6%.
M impact | EQUITY | Nov 05, 2026, 03:42 PM UTC
Cogent Communications Reports Third-Quarter Revenue of $231.2 Million
Cogent Communications' third-quarter service revenue fell 4.4% year over year, while its net loss narrowed. Revenue was pressured by cancellations of low-margin and non-core custom
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC
Weis Markets Reports Third-Quarter 2026 Revenue of $1.28 Billion, EPS of $0.90
Weis Markets said third-quarter revenue and earnings increased year over year. Higher fuel sales primarily drove sales growth, while higher gross profit increased gross margin; low
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC